Biogen Inc. Common Stock insider trading
BIIBfinancial statementsForm 4 filings on EDGAR156 transactions since Nov 1, 2024
From August 4, 2026 to November 1, 2026, 0 insiders at Biogen Inc. Common Stock bought $0 of stock in the open market, and 1 sold $119K. Officers and directors accounted for $0 of purchases and $119K of sales. The last reported transaction was an option exercise by Godbout Sean on October 2, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 5, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $119KAug 4, 2026 – Nov 1, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Oct 30, 2026. Insider data through Nov 1, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
156 transactions from November 1, 2024 to November 1, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Godbout Sean | Chief Accounting Officer | option exercise | 27 | $0.00 | — | 1,467 | Oct 5, 2026 |
| Oct 2, 2026 | Godbout Sean | Chief Accounting Officer | tax withholding | 8 | $219.88 | $2K | 1,459 | Oct 5, 2026 |
| Aug 4, 2026 | Minor Lloyd | Director | open-market sale10b5-1 | 593 | $200.96 | $119K | 2,689 | Aug 5, 2026 |
| Aug 3, 2026 | Minor Lloyd | Director | open-market sale10b5-1 | 593 | $203.34 | $121K | 3,282 | Aug 5, 2026 |
| Jun 9, 2026 | Hawkins William A | Director | award | 1,505 | $0.00 | — | 10,365 | Jun 11, 2026 |
| Jun 9, 2026 | Sherwin Stephen A | Director | award | 1,505 | $0.00 | — | 15,193 | Jun 11, 2026 |
| Jun 9, 2026 | Rowinsky Eric K | Director | award | 1,505 | $0.00 | — | 25,844 | Jun 11, 2026 |
| Jun 9, 2026 | Mantas Jesus B | Director | award | 1,505 | $0.00 | — | 11,263 | Jun 11, 2026 |
| Jun 9, 2026 | Langer Susan | Director | award | 1,505 | $0.00 | — | 6,634 | Jun 11, 2026 |
| Jun 9, 2026 | Patolawala Monish D | Director | award | 1,505 | $0.00 | — | 5,215 | Jun 11, 2026 |
| Jun 9, 2026 | Pangalos Menelas N | Director | option exercise | 2,370 | $0.00 | — | 2,370 | Jun 11, 2026 |
| Jun 9, 2026 | Pangalos Menelas N | Director | award | 1,505 | $0.00 | — | 3,875 | Jun 11, 2026 |
| Jun 9, 2026 | Minor Lloyd | Director | award | 1,505 | $0.00 | — | 3,875 | Jun 11, 2026 |
| Jun 9, 2026 | Freire Maria C | Director | award | 2,005 | $0.00 | — | 8,820 | Jun 11, 2026 |
| May 1, 2026 | Keeney Adam | Head of Corporate Development | option exercise | 939 | $0.00 | — | 6,820 | May 5, 2026 |
| May 1, 2026 | Keeney Adam | Head of Corporate Development | tax withholding | 455 | $187.06 | $85K | 6,365 | May 5, 2026 |
| Apr 1, 2026 | Godbout Sean | Chief Accounting Officer | option exercise | 181 | $0.00 | — | 1,396 | Apr 3, 2026 |
| Apr 1, 2026 | Godbout Sean | Chief Accounting Officer | tax withholding | 54 | $183.78 | $10K | 1,342 | Apr 3, 2026 |
| Feb 12, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | open-market buy | 3 | $195.04 | $585 | 19,611 | Feb 17, 2026 |
| Feb 9, 2026 | Singhal Priya | Head of Development | open-market sale10b5-1 | 2,660 | $199.83 | $532K | 8,043 | Feb 10, 2026 |
| Feb 6, 2026 | Viehbacher Christopher | President and CEO, Director | option exercise | 9,008 | $0.00 | — | 25,451 | Feb 10, 2026 |
| Feb 6, 2026 | Viehbacher Christopher | President and CEO, Director | tax withholding | 6,624 | $201.18 | $1M | 29,924 | Feb 10, 2026 |
| Feb 6, 2026 | Viehbacher Christopher | President and CEO, Director | option exercise | 15,453 | $0.00 | — | 36,548 | Feb 10, 2026 |
| Feb 6, 2026 | Viehbacher Christopher | President and CEO, Director | tax withholding | 4,356 | $201.18 | $876K | 21,095 | Feb 10, 2026 |
| Feb 6, 2026 | Singhal Priya | Head of Development | option exercise | 2,217 | $0.00 | — | 8,488 | Feb 10, 2026 |
| Feb 6, 2026 | Singhal Priya | Head of Development | tax withholding | 1,412 | $201.18 | $284K | 10,703 | Feb 10, 2026 |
| Feb 6, 2026 | Singhal Priya | Head of Development | option exercise | 4,683 | $0.00 | — | 12,115 | Feb 10, 2026 |
| Feb 6, 2026 | Singhal Priya | Head of Development | tax withholding | 1,056 | $201.18 | $212K | 7,432 | Feb 10, 2026 |
| Feb 6, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | tax withholding | 1,408 | $201.18 | $283K | 19,608 | Feb 10, 2026 |
| Feb 6, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | tax withholding | 914 | $201.18 | $184K | 16,333 | Feb 10, 2026 |
| Feb 6, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | option exercise | 1,940 | $0.00 | — | 17,247 | Feb 10, 2026 |
| Feb 6, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | tax withholding | 1,017 | $201.18 | $205K | 15,307 | Feb 10, 2026 |
| Feb 6, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | option exercise | 2,102 | $0.00 | — | 16,324 | Feb 10, 2026 |
| Feb 6, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | option exercise | 4,683 | $0.00 | — | 21,016 | Feb 10, 2026 |
| Feb 6, 2026 | Kramer Robin | Chief Financial Officer | option exercise | 703 | $0.00 | — | 9,231 | Feb 10, 2026 |
| Feb 6, 2026 | Kramer Robin | Chief Financial Officer | option exercise | 3,511 | $0.00 | — | 12,535 | Feb 10, 2026 |
| Feb 6, 2026 | Kramer Robin | Chief Financial Officer | tax withholding | 1,063 | $201.18 | $214K | 11,472 | Feb 10, 2026 |
| Feb 6, 2026 | Kramer Robin | Chief Financial Officer | tax withholding | 273 | $201.18 | $55K | 8,528 | Feb 10, 2026 |
| Feb 6, 2026 | Kramer Robin | Chief Financial Officer | option exercise | 789 | $0.00 | — | 8,801 | Feb 10, 2026 |
| Feb 6, 2026 | Kramer Robin | Chief Financial Officer | tax withholding | 207 | $201.18 | $42K | 9,024 | Feb 10, 2026 |
| Feb 6, 2026 | Keeney Adam | Head of Corporate Development | tax withholding | 994 | $201.18 | $200K | 5,881 | Feb 10, 2026 |
| Feb 6, 2026 | Keeney Adam | Head of Corporate Development | option exercise | 3,278 | $0.00 | — | 6,875 | Feb 10, 2026 |
| Feb 6, 2026 | Keeney Adam | Head of Corporate Development | option exercise | 1,802 | $0.00 | — | 4,186 | Feb 10, 2026 |
| Feb 6, 2026 | Keeney Adam | Head of Corporate Development | tax withholding | 589 | $201.18 | $118K | 3,597 | Feb 10, 2026 |
| Feb 6, 2026 | Izzar Rachid | Head of Global Product Strat. | option exercise | 2,044 | $0.00 | — | 8,204 | Feb 10, 2026 |
| Feb 6, 2026 | Izzar Rachid | Head of Global Product Strat. | tax withholding | 805 | $201.18 | $162K | 7,399 | Feb 10, 2026 |
| Feb 6, 2026 | Izzar Rachid | Head of Global Product Strat. | option exercise | 1,802 | $0.00 | — | 9,201 | Feb 10, 2026 |
| Feb 6, 2026 | Izzar Rachid | Head of Global Product Strat. | tax withholding | 458 | $201.18 | $92K | 8,743 | Feb 10, 2026 |
| Feb 6, 2026 | Izzar Rachid | Head of Global Product Strat. | tax withholding | 775 | $201.18 | $156K | 11,011 | Feb 10, 2026 |
| Feb 6, 2026 | Izzar Rachid | Head of Global Product Strat. | option exercise | 3,043 | $0.00 | — | 11,786 | Feb 10, 2026 |
Who the insiders are
Everyone who reported a transaction since November 1, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Singhal Priya | Head of Development | Feb 9, 2026 | open-market sale | 8,043 | — | $666K (2) | 2 of 2 |
| Minor Lloyd | Director | Aug 4, 2026 | open-market sale | 2,689 | — | $240K (2) | 2 of 2 |
| Murphy Nicole | Head of Pharm Ops and Tech | Feb 12, 2026 | open-market buy | 19,611 | $585 (1) | — | — |
| Kramer Robin | Chief Financial Officer | Feb 6, 2026 | option exercise | 9,231 | — | — | — |
| Alexander Susan H | EVP Chief Legal Officer | Feb 6, 2026 | option exercise | 43,321 | — | — | — |
| Izzar Rachid | Head of Global Product Strat. | Feb 6, 2026 | option exercise | 8,204 | — | — | — |
| Godbout Sean | Chief Accounting Officer | Oct 2, 2026 | option exercise | 1,467 | — | — | — |
| Gregory Ginger | EVP, Human Resources | Feb 6, 2026 | option exercise | 23,491 | — | — | — |
| Keeney Adam | Head of Corporate Development | May 1, 2026 | option exercise | 6,820 | — | — | — |
| Grogan Jane | Head of Research | Feb 6, 2026 | tax withholding | 4,058 | — | — | — |
| Viehbacher Christopher | President and CEO, Director | Feb 6, 2026 | option exercise | 25,451 | — | — | — |
| Mcdonnell Michael R | EVP, Chief Financial Officer | Feb 10, 2025 | option exercise | 25,712 | — | — | — |
| Sherwin Stephen A | Director | Jun 9, 2026 | award | 15,193 | — | — | — |
| Hawkins William A | Director | Jun 9, 2026 | award | 10,365 | — | — | — |
| Rowinsky Eric K | Director | Jun 9, 2026 | award | 25,844 | — | — | — |
| Mantas Jesus B | Director | Jun 9, 2026 | award | 11,263 | — | — | — |
| Langer Susan | Director | Jun 9, 2026 | award | 6,634 | — | — | — |
| Patolawala Monish D | Director | Jun 9, 2026 | award | 5,215 | — | — | — |
| Pangalos Menelas N | Director | Jun 9, 2026 | option exercise | 2,370 | — | — | — |
| Freire Maria C | Director | Jun 9, 2026 | award | 8,820 | — | — | — |
| Dorsa Caroline | Director | Jun 17, 2025 | award | 31,002 | — | — | — |
Questions
Are Biogen Inc. Common Stock insiders buying or selling?
Over the twelve months to November 1, 2026, 2 insiders at Biogen Inc. Common Stock sold $905K of stock in the open market, all by officers and directors, and 1 insider bought $585, all by officers and directors. Net, insiders sold $905K. Only open-market purchases and sales are counted.
Who sold the most Biogen Inc. Common Stock stock in the last year?
Singhal Priya (Head of Development) sold $666K in 2 open-market sales over the twelve months to November 1, 2026.
Do Biogen Inc. Common Stock executives sell under 10b5-1 plans?
4 of the 4 open-market sales in the last twelve months (100%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Biogen Inc. Common Stock
- Biogen Inc. Common Stock financial statements
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.